

## Annual meeting of the Swedish AML Group 2025

**Venue:** Victory Hotel, Lilla Nygatan 5, Old town, Stockholm  
or via TEAMS: Click here to join the meeting ([Anslut till mötet nu](#))

**Date:** Friday 17 January 2025

**08:30-09:20 ANNUAL MEETING OF SWEDISH AML GROUP (open pre-meeting, in Swedish)**

08:30-08:55 Swedish AML Steering Group meeting

08:55-09:05 Report of activities from the Swedish AML Group (Vladimir Lazarevic, Lund)

09:05-09:20 News from the Nordic AML Group (Sören Lehmann and Albin Österroos, Uppsala)

**09:20-09:40 *Coffee and leg stretch***

**09:40-09:45 WELCOME** (Vladimir Lazarevic, Lund, chairman of the Swedish AML Group)

**09:45-10:50 TRANSLATIONAL SESSION: The role of cladribine in de novo and R/R AML**

(Chair: Martin Jädersten, Karolinska)

09:45-10:30 **Keynote lecture:** Agnieszka Wierzbowska, Lodz, Poland

10:30-10:50 Discussion

**10:50-11:00 *Leg stretch***

**11:00-12:00 SWEDISH AML REGISTRY AND STUDIES FROM SWEDEN** (chair: Albin Österroos)

11:00-11:20 Report from the Swedish AML registry (Gunnar Juliusson and Christer Nilsson)

11:20-11:40 SLAMF6 – a novel target for immune therapy of AML (Niklas Landberg, Lund)

11:40-12:00 To be determined

**12:00-13:00 *Lunch***

**13:00-14:00 CLINICAL FOCUS SESSION: MPAL** (chair: Ellinor Janneson, Umeå)

13:00-13:20 Classification (Anna Porwit, Lund/Stockholm)

13:20-13:45 New treatment guidelines (Helene Hallböök, Uppsala)

13:45-14:00 Discussion

**14:00-14:20 *Coffee and leg stretch***

**14:20-15:30 CLINICAL TRIAL UPDATE** (chair: Anna Robelius)

14:20-14:30 HEAT-AML, enrolment complete, prel results (Martin Jädersten, Stockholm)

14:30-14:40 LD-VenEx, report of interim analysis (Martin Jädersten, Stockholm)

14:40-14:50 MATTEO, update (Stefan Deneberg, Stockholm)

14:50-15:00 FLASH-IV (Christer Nilsson, Stockholm)

15:00-15:15 HOVON 150 and 156 enrolment complete, 173 and 177, updates  
(Martin Höglund and Vladimir Lazarevic, Lund)

15:15-15:30 Overview of other studies ongoing or in pipeline (Vladimir Lazarevic, Lund)

**15:30-15:35 Concluding remarks** (Vladimir Lazarevic, Lund)